Diabetic cardiomyopathy: Signaling defects and therapeutic approaches

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 3, 2010, Pages 373-391

  Dobrin, Joseph S ^a   Lebeche, Djamel ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Adipokines; Antihyperglycemic drugs; Calcium cycling; Diabetic cardiomyopathy; Gene therapy; Glucotoxicity; Insulin resistance; Lipotoxicity; Mitochondrial dysfunction; Obesity; Stem cell therapy

Indexed keywords

ADIPONECTIN; ALBIGLUTIDE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BEZAFIBRATE; BIGUANIDE DERIVATIVE; CALCIUM; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; FIBRIC ACID DERIVATIVE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INSULIN; LEPTIN; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PYRIDOXAMINE; RESISTIN; ROSIGLITAZONE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; UNINDEXED DRUG;

CALCIUM HOMEOSTASIS; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CYTOKINE RELEASE; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIABETIC HYPERTENSION; DIABETIC PATIENT; DIASTOLIC DYSFUNCTION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; EXCITATION CONTRACTION COUPLING; HEART FAILURE; HEART HYPERTROPHY; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HEART PERFORMANCE; HUMAN; HYPERPHAGIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KINESIOTHERAPY; LIPID OXIDATION; LIVER TOXICITY; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WEIGHT GAIN;

ADIPOKINES; BLOOD GLUCOSE; CALCIUM SIGNALING; CARDIOMYOPATHIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MITOCHONDRIA, HEART; PROGNOSIS; RISK ASSESSMENT;

EID: 77949460107     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.17     Document Type: Review

References (205)

1. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 59(1), 8-13 (1979).
2. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol. 30(6), 595-602 (1972).
3. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ. Res. 98(5), 596-605 (2006).
4. Davidoff AJ. Convergence of glucose-and fatty acid-induced abnormal myocardial excitation-contraction coupling and insulin signalling. Clin. Exp. Pharmacol. Physiol. 33(1-2), 152-158 (2006).
5. Frustaci A, Kajstura J, Chimenti C, et al. Myocardial cell death in human diabetes. Circ. Res. 87(12), 1123-1132 (2000).
6. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr. Rev. 25(4), 543-567 (2004).
7. Carugo S, Giannattasio C, Calchera I et al. Progression of functional and structural cardiac alterations in young normotensive uncomplicated patients with Type 1 diabetes mellitus. J. Hypertens. 19(9), 1675-1680 (2001).
8. Schannwell CM, Schneppenheim M, Perings S, Plehn G, Strauer BE. Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology 98(1-2), 33-39 (2002).
9. Aneja A, Tang WH, Bansilal S, Garcia MJ, Farkouh ME. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am. J. Med. 121(9), 748-757 (2008).
10. An D, Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 291(4), H1489-H1506 (2006).
11. Lopaschuk GD, Belke DD, Gamble J, Itoi T, Schonekess BO. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim. Biophys. Acta 1213(3), 263-276 (1994).
12. Goodwin GW, Taegtmeyer H. Regulation of fatty acid oxidation of the heart by MCD and ACC during contractile stimulation. Am. J. Physiol. 277(4 Pt 1), E772-E777 (1999).
13. Kudo N, Barr AJ, Barr RL, Desai S, Lopaschuk GD. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5'-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J. Biol. Chem. 270(29), 17513-17520 (1995).
14. Moller DE. New drug targets for Type 2 diabetes and the metabolic syndrome. Nature 414(6865), 821-827 (2001).
15. Saunders J, Mathewkutty S, Drazner MH, McGuire DK. Cardiomyopathy in Type 2 diabetes: update on pathophysiological mechanisms. Herz 33(3), 184-190 (2008).
16. Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, Kelly DP. Peroxisome proliferator-activated receptor g coactivator-1 promotes cardiac mitochondrial biogenesis. J. Clin. Invest. 106(7), 847-856 (2000).
17. Lopaschuk GD, Folmes CD, Stanley WC. Cardiac energy metabolism in obesity. Circ. Res. 101(4), 335-347 (2007).
18. Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor a (PPARa) in the cellular fasting response: the PPARa-null mouse as a model of fatty acid oxidation disorders. Proc. Natl Acad. Sci. USA 96(13), 7473-7478 (1999).
19. Finck BN, Lehman JJ, Leone TC et al. The cardiac phenotype induced by PPARa overexpression mimics that caused by diabetes mellitus. J. Clin. Invest. 109(1), 121-130 (2002).
20. Boudina S, Sena S, O'Neill BT, Tathireddy P, Young ME, Abel ED. Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation 112(17), 2686-2695 (2005).
21. Peterson LR, Herrero P, Schechtman KB et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 109(18), 2191-2196 (2004).
22. Lee Y, Naseem RH, Duplomb L et al. Hyperleptinemia prevents lipotoxic cardiomyopathy in acyl CoA synthase transgenic mice. Proc. Natl Acad. Sci. USA 101(37), 13624-13629 (2004).
23. Lowell BB, Shulman GI. Mitochondrial dysfunction and Type 2 diabetes. Science 307(5708), 384-387 (2005).
24. Savage DB, Petersen KF, Shulman GI. Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension 45(5), 828-833 (2005).
25. Unger RH. Lipotoxic diseases. Annu. Rev. Med. 53, 319-336 (2002).
26. Zhou YT, Grayburn P, Karim A et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc. Natl Acad. Sci. USA 97(4), 1784-1789 (2000).
27. Son NH, Park TS, Yamashita H et al. Cardiomyocyte expression of PPARg leads to cardiac dysfunction in mice. J. Clin. Invest. 117(10), 2791-2801 (2007).
28. Susic D, Varagic J, Ahn J, Frohlich ED. Collagen cross-link breakers: a beginning of a new era in the treatment of cardiovascular changes associated with aging, diabetes, and hypertension. Curr. Drug Targets Cardiovasc. Haematol. Disord. 4(1), 97-101 (2004).
29. Folmes CD, Clanachan AS, Lopaschuk GD. Fatty acids attenuate insulin regulation of 5́-AMP-activated protein kinase and insulin cardioprotection after ischemia. Circ. Res. 99(1), 61-68 (2006).
30. Bidasee KR, Nallani K, Yu Y et al. Chronic diabetes increases advanced glycation end products on cardiac ryanodine receptors/ calcium-release channels. Diabetes 52(7), 1825-1836 (2003).
31. Bidasee KR, Zhang Y, Shao CH et al. Diabetes increases formation of advanced glycation end products on Sarco(endo) plasmic reticulum Ca2+-ATPase. Diabetes 53(2), 463-473 (2004).
32. Fulop N, Marchase RB, Chatham JC. Role of protein O-linked N-acetyl-glucosamine in mediating cell function and survival in the cardiovascular system. Cardiovasc. Res. 73(2), 288-297 (2007).
33. Abel ED. Myocardial insulin resistance and cardiac complications of diabetes. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5(2), 219-226 (2005).
34. Ouwens DM, Diamant M. Myocardial insulin action and the contribution of insulin resistance to the pathogenesis of diabetic cardiomyopathy. Arch. Physiol. Biochem. 113(2), 76-86 (2007).
35. Witteles RM, Fowler MB. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J. Am. Coll. Cardiol. 51(2), 93-102 (2008).
36. Pang TT, Narendran P. Addressing insulin resistance in Type 1 diabetes. Diabet. Med. 25(9), 1015-1024 (2008).
37. Zick Y. Ser/Thr phosphorylation of IRS proteins: a molecular basis for insulin resistance. Sci. STKE 2005(268), pe4 (2005).
38. Kim JA, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin resistance. Circ. Res. 102(4), 401-414 (2008).
39. Zhande R, Mitchell JJ, Wu J, Sun XJ. Molecular mechanism of insulin-induced degradation of insulin receptor substrate 1. Mol. Cell. Biol. 22(4), 1016-1026 (2002).
40. Egawa K, Maegawa H, Shimizu S et al. Protein-tyrosine phosphatase-1B negatively regulates insulin signaling in l6 myocytes and Fao hepatoma cells. J. Biol. Chem. 276(13), 10207-10211 (2001).
41. Vinciguerra M, Foti M. PTEN and SHIP2 phosphoinositide phosphatases as negative regulators of insulin signalling. Arch. Physiol. Biochem. 112(2), 89-104 (2006).
42. Hardie DG, Carling D, Carlson M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Annu. Rev. Biochem. 67, 821-855 (1998).
43. Kim JK, Fillmore JJ, Sunshine MJ et al. PKC-q knockout mice are protected from fat-induced insulin resistance. J. Clin. Invest. 114(6), 823-827 (2004).
44. Purdham DM, Zou MX, Rajapurohitam V, Karmazyn M. Rat heart is a site of leptin production and action. Am. J. Physiol. Heart Circ. Physiol. 287(6), H2877-H2884 (2004).
45. Kloek C, Haq AK, Dunn SL, Lavery HJ, Banks AS, Myers MG Jr. Regulation of JAK kinases by intracellular leptin receptor sequences. J. Biol. Chem. 277(44), 41547-41555 (2002).
46. White DW, Kuropatwinski KK, Devos R, Baumann H, Tartaglia LA. Leptin receptor (OB-R) signaling. Cytoplasmic domain mutational analysis and evidence for receptor homo-oligomerization. J. Biol. Chem. 272(7), 4065-4071 (1997).
47. Banks AS, Davis SM, Bates SH, Myers MG Jr. Activation of downstream signals by the long form of the leptin receptor. J. Biol. Chem. 275(19), 14563-14572 (2000).
48. Eyckerman S, Broekaert D, Verhee A, Vandekerckhove J, Tavernier J. Identification of the Y985 and Y1077 motifs as SOCS3 recruitment sites in the murine leptin receptor. FEBS Lett. 486(1), 33-37 (2000).
49. Munzberg H, Bjornholm M, Bates SH, Myers MG Jr. Leptin receptor action and mechanisms of leptin resistance. Cell. Mol. Life Sci. 62(6), 642-652 (2005).
50. Bates SH, Myers MG. The role of leptin-STAT3 signaling in neuroendocrine function: an integrative perspective. J. Mol. Med. 82(1), 12-20 (2004).
51. Dunn SL, Bjornholm M, Bates SH, Chen Z, Seifert M, Myers MG Jr. Feedback inhibition of leptin receptor/JAK2 signaling via Tyr1138 of the leptin receptor and suppressor of cytokine signaling 3. Mol. Endocrinol. 19(4), 925-938 (2005).
52. Karmazyn M, Kilic A, Javadov S. The role of NHE-1 in myocardial hypertrophy and remodelling. J. Mol. Cell. Cardiol. 44(4), 647-653 (2008).
53. Nickola MW, Wold LE, Colligan PB, Wang GJ, Samson WK, Ren J. Leptin attenuates cardiac contraction in rat ventricular myocytes. Role of NO. Hypertension 36(4), 501-505 (2000).
54. Rajapurohitam V, Javadov S, Purdham DM, Kirshenbaum LA, Karmazyn M. An autocrine role for leptin in mediating the cardiomyocyte hypertrophic effects of angiotensin II and endothelin-1. J. Mol. Cell. Cardiol. 41(2), 265-274 (2006).
55. Zeidan A, Javadov S, Karmazyn M. Essential role of Rho/ROCK-dependent processes and actin dynamics in mediating leptin-induced hypertrophy in rat neonatal ventricular myocytes. Cardiovasc. Res. 72(1), 101-111 (2006).
56. Zeidan A, Javadov S, Chakrabarti S, Karmazyn M. Leptin-induced cardiomyocyte hypertrophy involves selective caveolae and RhoA/ROCK-dependent p38 MAPK translocation to nuclei. Cardiovasc. Res. 77(1), 64-72 (2008).
57. Karmazyn M, Purdham DM, Rajapurohitam V, Zeidan A. Leptin as a cardiac hypertrophic factor: a potential target for therapeutics. Trends Cardiovasc. Med. 17(6), 206-211 (2007).
58. Smith CC, Mocanu MM, Davidson SM, Wynne AM, Simpkin JC, Yellon DM. Leptin, the obesity-associated hormone, exhibits direct cardioprotective effects. Br. J. Pharmacol. 149(1), 5-13 (2006).
59. McGaffin KR, Sun CK, Rager JJ et al. Leptin signalling reduces the severity of cardiac dysfunction and remodelling after chronic ischaemic injury. Cardiovasc. Res. 77(1), 54-63 (2008).
60. Palanivel R, Eguchi M, Shuralyova I, Coe I, Sweeney G. Distinct effects of short- and long-term leptin treatment on glucose and fatty acid uptake and metabolism in HL-1 cardiomyocytes. Metabolism 55(8), 1067-1075 (2006).
61. Atkinson LL, Fischer MA, Lopaschuk GD. Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylase-malonyl-CoA axis. J. Biol. Chem. 277(33), 29424-29430 (2002).
62. Haap M, Houdali B, Maerker E et al. Insulin-like effect of low-dose leptin on glucose transport in Langendorff rat hearts. Exp. Clin. Endocrinol. Diabetes 111(3), 139-145 (2003).
63. Lee Y, Wang MY, Kakuma T et al. Liporegulation in diet-induced obesity. The antisteatotic role of hyperleptinemia. J. Biol. Chem. 276(8), 5629-5635 (2001).
64. Christoffersen C, Bollano E, LindegaardML et al. Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. Endocrinology 144(8), 3483-3490 (2003).
65. Young ME, Guthrie PH, Razeghi P et al. Impaired long-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. Diabetes 51(8), 2587-2595 (2002).
66. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and Type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 86(5), 1930-1935 (2001).
67. Mohan V, Deepa R, Pradeepa R et al. Association of low adiponectin levels with the metabolic syndrome - the Chennai Urban Rural Epidemiology Study (CURES-4). Metabolism 54(4), 476-481 (2005).
68. Iwashima Y, Katsuya T, Ishikawa K et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43(6), 1318-1323 (2004).
69. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291(14), 1730-1737 (2004).
70. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. Adiponectin and future coronary heart disease events among men with Type 2 diabetes. Diabetes 54(2), 534-539 (2005).
71. Takano H, Obata JE, Kodama Y et al. Adiponectin is released from the heart in patients with heart failure. Int. J. Cardiol. 132(2), 221-226 (2009).
72. Lawlor DA, Davey Smith G, Ebrahim S, Thompson C, Sattar N. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J. Clin. Endocrinol. Metab. 90(10), 5677-5683 (2005).
73. Shibata R, Ouchi N, Ito M et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat. Med. 10(12), 1384-1389 (2004).
74. Liao Y, Takashima S, Maeda N et al. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc. Res. 67(4), 705-713 (2005).
75. Shibata R, Sato K, Pimentel DR et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat. Med. 11(10), 1096-1103 (2005).
76. Tao L, Gao E, Jiao X et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 115(11), 1408-1416 (2007).
77. Karmazyn M, Purdham DM, Rajapurohitam V, Zeidan A. Signaling mechanisms underlying the metabolic and other effects of adipokines on the heart. Cardiovasc. Res. 79(2), 279-286 (2008).
78. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 409(6818), 307-312 (2001).
79. Rajala MW, Lin Y, Ranalletta M et al. Cell type-specific expression and coregulation of murine resistin and resistin-like molecule-a in adipose tissue. Mol. Endocrinol. 16(8), 1920-1930 (2002).
80. Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol. Metab. 13(1), 18-23 (2002).
81. Palanivel R, Maida A, Liu Y, Sweeney G. Regulation of insulin signalling, glucose uptake and metabolism in rat skeletal muscle cells upon prolonged exposure to resistin. Diabetologia 49(1), 183-190 (2006).
82. Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated Type II diabetic patients. Int. J. Obes. Relat. Metab. Disord. 28(6), 783-789 (2004).
83. Heilbronn LK, Rood J, Janderova L et al. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J. Clin. Endocrinol. Metab. 89(4), 1844-1848 (2004).
84. Lee JH, Chan JL, Yiannakouris N et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J. Clin. Endocrinol. Metab. 88(10), 4848-4856 (2003).
85. Kim M, Oh JK, Sakata S et al. Role of resistin in cardiac contractility and hypertrophy. J. Mol. Cell. Cardiol. 45(2), 270-280 (2008).
86. Graveleau C, Zaha VG, Mohajer A et al. Mouse and human resistins impair glucose transport in primary mouse cardiomyocytes, and oligomerization is required for this biological action. J. Biol. Chem. 280(36), 31679-31685 (2005).
87. Wang BW, Hung HF, Chang H, Kuan P, Shyu KG. Mechanical stretch enhances the expression of resistin gene in cultured cardiomyocytes via tumor necrosis factor-a. Am. J. Physiol. Heart Circ. Physiol. 293(4), H2305-H2312 (2007).
88. Ghosh S, Singh AK, Aruna B, Mukhopadhyay S, Ehtesham NZ. The genomic organization of mouse resistin reveals major differences from the human resistin: functional implications. Gene 305(1), 27-34 (2003).
89. Pischon T, Bamberger CM, Kratzsch J et al. Association of plasma resistin levels with coronary heart disease in women. Obes. Res. 13(10), 1764-1771 (2005).
90. Takeishi Y, Niizeki T, Arimoto T et al. Serum resistin is associated with high risk in patients with congestive heart failure - a novel link between metabolic signals and heart failure. Circ. J. 71(4), 460-464 (2007).
91. Burnett MS, Devaney JM, Adenika RJ, Lindsay R, Howard BV. Cross-sectional associations of resistin, coronary heart disease, and insulin resistance. J. Clin. Endocrinol. Metab. 91(1), 64-68 (2006).
92. McTernan PG, Fisher FM, Valsamakis G et al. Resistin and Type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J. Clin. Endocrinol. Metab. 88(12), 6098-6106 (2003).
93. Efstathiou SP, Tsiakou AG, Tsioulos DI et al. Prognostic significance of plasma resistin levels in patients with atherothrombotic ischemic stroke. Clin. Chim. Acta 378(1-2), 78-85 (2007).
94. Endoh M. Signal transduction and Ca2+ signaling in intact myocardium. J. Pharmacol. Sci. 100(5), 525-537 (2006).
95. Hove-Madsen L, Bers DM. Sarcoplasmic reticulum Ca2+ uptake and thapsigargin sensitivity in permeabilized rabbit and rat ventricular myocytes. Circ. Res. 73(5), 820-828 (1993).
96. Li L, Chu G, Kranias EG, Bers DM. Cardiac myocyte calcium transport in phospholamban knockout mouse: relaxation and endogenous CaMKII effects. Am. J. Physiol. 274(4 Pt 2), H1335-H1347 (1998).
97. Choi KM, Zhong Y, Hoit BD et al. Defective intracellular Ca2+ signaling contributes to cardiomyopathy in Type 1 diabetic rats. Am. J. Physiol. Heart Circ. Physiol. 283(4), H1398-H1408 (2002).
98. Pereira L, Matthes J, Schuster I et al. Mechanisms of [Ca2+]i transient decrease in cardiomyopathy of db/db Type 2 diabetic mice. Diabetes 55(3), 608-615 (2006).
99. Marx SO, Reiken S, Hisamatsu Y et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101(4), 365-376 (2000).
100. Yaras N, Ugur M, Ozdemir S et al. Effects of diabetes on ryanodine receptor Ca release channel (RyR2) and Ca2+ homeostasis in rat heart. Diabetes 54(11), 3082-3088 (2005).
101. Lehnart SE, Maier LS, Hasenfuss G. Abnormalities of calcium metabolism and myocardial contractility depression in the failing heart. Heart Fail. Rev. 14(4), 213-224 (2009).
102. Reiken S, Gaburjakova M, Guatimosim S et al. Protein kinase A phosphorylation of the cardiac calcium release channel (ryanodine receptor) in normal and failing hearts. Role of phosphatases and response to isoproterenol. J. Biol. Chem. 278(1), 444-453 (2003).
103. Marks AR. Ryanodine receptors/calcium release channels in heart failure and sudden cardiac death. J. Mol. Cell. Cardiol. 33(4), 615-624 (2001).
104. Lebeche D, Davidoff AJ, Hajjar RJ. Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy. Nat. Clin. Pract. Cardiovasc. Med. 5(11), 715-724 (2008).
105. Zhong Y, Ahmed S, Grupp IL, Matlib MA. Altered SR protein expression associated with contractile dysfunction in diabetic rat hearts. Am. J. Physiol. Heart Circ. Physiol. 281(3), H1137-H1147 (2001).
106. Sakata S, Lebeche D, Sakata Y et al. Mechanical and metabolic rescue in a Type II diabetes model of cardiomyopathy by targeted gene transfer. Mol. Ther. 13(5), 987-996 (2006).
107. Belke DD, Swanson EA, Dillmann WH. Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart. Diabetes 53(12), 3201-3208 (2004).
108. Catalucci D, Latronico MV, Ceci M et al. Akt increases sarcoplasmic reticulum Ca2+ cycling by direct phosphorylation of phospholamban at Thr17. J. Biol. Chem. 284(41), 28180-28187 (2009).
109. Wold LE, Dutta K, Mason MM et al. Impaired SERCA function contributes to cardiomyocyte dysfunction in insulin resistant rats. J. Mol. Cell. Cardiol. 39(2), 297-307 (2005).
110. Trost SU, Belke DD, Bluhm WF, Meyer M, Swanson E, Dillmann WH. Overexpression of the sarcoplasmic reticulum Ca2+-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes 51(4), 1166-1171 (2002).
111. del Monte F, Harding SE, Schmidt U et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 100(23), 2308-2311 (1999).
112. Ranu HK, Terracciano CM, Davia K et al. Effects of Na+/Ca2+-exchanger overexpression on excitation-contraction coupling in adult rabbit ventricular myocytes. J. Mol. Cell. Cardiol. 34(4), 389-400 (2002).
113. Hattori Y, Matsuda N, Kimura J et al. Diminished function and expression of the cardiac Na+-Ca2+ exchanger in diabetic rats: implication in Ca2+ overload. J. Physiol. 527(Pt 1), 85-94 (2000).
114. Chattou S, Diacono J, Feuvray D. Decrease in sodium-calcium exchange and calcium currents in diabetic rat ventricular myocytes. Acta Physiol. Scand. 166(2), 137-144 (1999).
115. Wang DW, Kiyosue T, Shigematsu S, Arita M. Abnormalities of K+ and Ca2+ currents in ventricular myocytes from rats with chronic diabetes. Am. J. Physiol. 269(4 Pt 2), H1288-H1296 (1995).
116. Lu Z, Jiang YP, Xu XH, Ballou LM, Cohen IS, Lin RZ. Decreased l-type Ca2+ current in cardiac myocytes of Type 1 diabetic Akita mice due to reduced phosphatidylinositol 3-kinase signaling. Diabetes 56(11), 2780-2789 (2007).
117. Shimoni Y, Firek L, Severson D, Giles W. Short-term diabetes alters K+ currents in rat ventricular myocytes. Circ. Res. 74(4), 620-628 (1994).
118. Shimoni Y, Liu XF. Role of PKC in autocrine regulation of rat ventricular K+ currents by angiotensin and endothelin. Am. J. Physiol. Heart Circ. Physiol. 284(4), H1168-H1181 (2003).
119. Liu GX, Hanley PJ, Ray J, Daut J. Long-chain acyl-coenzyme A esters and fatty acids directly link metabolism to K(ATP) channels in the heart. Circ. Res. 88(9), 918-924 (2001).
120. Malhotra A, Sanghi V. Regulation of contractile proteins in diabetic heart. Cardiovasc. Res. 34(1), 34-40 (1997).
121. Jweied EE, McKinney RD, Walker LA et al. Depressed cardiac myofilament function in human diabetes mellitus. Am. J. Physiol. Heart Circ. Physiol. 289(6), H2478-H2483 (2005).
122. Akella AB, Ding XL, Cheng R, Gulati J. Diminished Ca2+ sensitivity of skinned cardiac muscle contractility coincident with troponin T-band shifts in the diabetic rat. Circ. Res. 76(4), 600-606 (1995).
123. Dillmann WH. Diabetes mellitus induces changes in cardiac myosin of the rat. Diabetes 29(7), 579-582 (1980).
124. Rajabi M, Kassiotis C, Razeghi P, Taegtmeyer H. Return to the fetal gene program protects the stressed heart: a strong hypothesis. Heart Fail. Rev. 12(3-4), 331-343 (2007).
125. Rolo AP, Palmeira CM. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol. Appl. Pharmacol. 212(2), 167-178 (2006).
126. Santos DL, Palmeira CM, Seica R et al. Diabetes and mitochondrial oxidative stress: a study using heart mitochondria from the diabetic Goto-Kakizaki rat. Mol. Cell. Biochem. 246(1-2), 163-170 (2003).
127. Shen X, Zheng S, Thongboonkerd V et al. Cardiac mitochondrial damage and biogenesis in a chronic model of Type 1 diabetes. Am. J. Physiol. Endocrinol. Metab. 287(5), E896-E905 (2004).
128. Palmer JW, Tandler B, Hoppel CL. Biochemical properties of subsarcolemmal and interfibrillar mitochondria isolated from rat cardiac muscle. J. Biol. Chem. 252(23), 8731-8739 (1977).
129. Riva A, Tandler B, Loffredo F, Vazquez E, Hoppel C. Structural differences in two biochemically defined populations of cardiac mitochondria. Am. J. Physiol. Heart Circ. Physiol. 289(2), H868-H872 (2005).
130. Adhihetty PJ, Ljubicic V, Menzies KJ, Hood DA. Differential susceptibility of subsarcolemmal and intermyofibrillar mitochondria to apoptotic stimuli. Am. J. Physiol. Cell Physiol. 289(4), C994-C1001 (2005).
131. Koves TR, Noland RC, Bates AL, Henes ST, Muoio DM, Cortright RN. Subsarcolemmal and intermyofibrillar mitochondria play distinct roles in regulating skeletal muscle fatty acid metabolism. Am. J. Physiol. Cell Physiol. 288(5), C1074-C1082 (2005).
132. Mollica MP, Lionetti L, Crescenzo R et al. Heterogeneous bioenergetic behaviour of subsarcolemmal and intermyofibrillar mitochondria in fed and fasted rats. Cell. Mol. Life Sci. 63(3), 358-366 (2006).
133. Ritov VB, Menshikova EV, He J, Ferrell RE, Goodpaster BH, Kelley DE. Deficiency of subsarcolemmal mitochondria in obesity and Type 2 diabetes. Diabetes 54(1), 8-14 (2005).
134. Williamson CL, Dabkowski ER, Baseler WA, Croston TL, Alway SE, Hollander JM. Enhanced apoptotic propensity in diabetic cardiac mitochondria: influence of subcellular spatial location. Am. J. Physiol. Heart Circ. Physiol. 298(2), H633-H642 (2010).
135. Hood DA. Invited review: contractile activity-induced mitochondrial biogenesis in skeletal muscle. J. Appl. Physiol. 90(3), 1137-1157 (2001).
136. Dabkowski ER, Williamson CL, Bukowski VC et al. Diabetic cardiomyopathy-associated dysfunction in spatially distinct mitochondrial subpopulations. Am. J. Physiol. Heart Circ. Physiol. 296(2), H359-H369 (2009).
137. Neubauer S, Horn M, Cramer M et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96(7), 2190-2196 (1997).
138. Spindler M, Saupe KW, Tian R, Ahmed S, Matlib MA, Ingwall JS. Altered creatine kinase enzyme kinetics in diabetic cardiomyopathy. A31P NMR magnetization transfer study of the intact beating rat heart. J. Mol. Cell. Cardiol. 31(12), 2175-2189 (1999).
139. del Monte F, Williams E, Lebeche D et al. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca2+-ATPase in a rat model of heart failure. Circulation 104(12), 1424-1429 (2001).
140. Scheuermann-Freestone M, Madsen PL, Manners D et al. Abnormal cardiac and skeletal muscle energy metabolism in patients with Type 2 diabetes. Circulation 107(24), 3040-3046 (2003).
141. Szabadkai G, Duchen MR. Mitochondria: the hub of cellular Ca2+ signaling. Physiology (Bethesda) 23, 84-94 (2008).
142. Murgia M, Giorgi C, Pinton P, Rizzuto R. Controlling metabolism and cell death: at the heart of mitochondrial calcium signalling. J. Mol. Cell. Cardiol. 46(6), 781-788 (2009).
143. Balaban RS. Cardiac energy metabolism homeostasis: role of cytosolic calcium. J. Mol. Cell. Cardiol. 34(10), 1259-1271 (2002).
144. Hansford RG, Zorov D. Role of mitochondrial calcium transport in the control of substrate oxidation. Mol. Cell. Biochem. 184(1-2), 359-369 (1998).
145. Jouaville LS, Pinton P, Bastianutto C, Rutter GA, Rizzuto R. Regulation of mitochondrial ATP synthesis by calcium: evidence for a long-term metabolic priming. Proc. Natl Acad. Sci. USA 96(24), 13807-13812 (1999).
146. Tian R, Halow JM, Meyer M et al. Thermodynamic limitation for Ca2+ handling contributes to decreased contractile reserve in rat hearts. Am. J. Physiol. 275(6 Pt 2), H2064-H2071 (1998).
147. Zaman AK, Fujii S, Goto D et al. Salutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity. J. Mol. Cell. Cardiol. 37(2), 525-535 (2004).
148. Kawasaki D, Kosugi K, Waki H, Yamamoto K, Tsujino T, Masuyama T. Role of activated renin-angiotensin system in myocardial fibrosis and left ventricular diastolic dysfunction in diabetic patients - reversal by chronic angiotensin II Type 1A receptor blockade. Circ. J. 71(4), 524-529 (2007).
149. Orea-Tejeda A, Colin-Ramirez E, Castillo-Martinez L et al. Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients. Rev. Invest. Clin. 59(2), 103-107 (2007).
150. Duncker DJ, Van Zon NS, Altman JD, Pavek TJ, Bache RJ. Role of K+ATP channels in coronary vasodilation during exercise. Circulation 88(3), 1245-1253 (1993).
151. Ballagi-Pordany G, Koszeghy A, Koltai MZ, Aranyi Z, Pogatsa G. Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds. Diabetes Res. Clin. Pract. 8(2), 109-114 (1990).
152. Klepzig H, Kober G, Matter C et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur. Heart J. 20(6), 439-446 (1999).
153. Hu S, Wang S, Dunning BE. Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide. Int. J. Exp. Diabetes Res. 2(1), 63-72 (2001).
154. Fisman EZ, Tenenbaum A. A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovasc. Diabetol. 8, 38 (2009).
155. Johnson JA, Simpson SH, Toth EL, Majumdar SR. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes. Diabet. Med. 22(4), 497-502 (2005).
156. Adams JF, Clark JS, Ireland JT, Kesson CM, Watson WS. Malabsorption of vitamin B12 and intrinsic factor secretion during biguanide therapy. Diabetologia 24(1), 16-18 (1983).
157. Goldner MG, Knatterud GL, Prout TE. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results. JAMA 218(9), 1400-1410 (1971).
158. Gundewar S, Calvert JW, Jha S et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ. Res. 104(3), 403-411 (2009).
159. DeFronzo RA. Pharmacologic therapy for Type 2 diabetes mellitus. Ann. Intern. Med. 131(4), 281-303 (1999).
160. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin excretion in Type II diabetes. J. Hum. Hypertens. 17(1), 7-12 (2003).
161. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356(24), 2457-2471 (2007).
162. Harris G. Research ties diabetes drug to heart woes. New York Times, 19 February 2010.
163. Fazio S. More clinical lessons from the FIELD study. Cardiovasc. Drugs Ther. 23(3), 235-241 (2009).
164. Dewald O, Sharma S, Adrogue J et al. Downregulation of peroxisome proliferator-activated receptor-a gene expression in a mouse model of ischemic cardiomyopathy is dependent on reactive oxygen species and prevents lipotoxicity. Circulation 112(3), 407-415 (2005).
165. Tenenbaum A, Fisman EZ, Boyko V et al. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch. Intern. Med. 166(7), 737-741 (2006).
166. Hiuge A, Tenenbaum A, Maeda N et al. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler. Thromb. Vasc. Biol. 27(3), 635-641 (2007).
167. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch. Intern. Med. 165(10), 1154-1160 (2005).
168. Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: thebezafibrate lessons. Cardiovasc. Diabetol. 4, 14 (2005).
169. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. J. Clin. Invest. 46(12), 1954-1962 (1967).
170. Burcelin R. The incretins: a link between nutrients and well-being. Br. J. Nutr. 93(Suppl. 1), S147-S156 (2005).
171. Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with Type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28(5), 1083-1091 (2005).
172. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137(7), 2968-2978 (1996).
173. Nikolaidis LA, Elahi D, Hentosz T et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110(8), 955-961 (2004).
174. Nikolaidis LA, Mankad S, Sokos GG et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109(8), 962-965 (2004).
175. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in Type 2 diabetes: systematic review and meta-analysis. JAMA 298(2), 194-206 (2007).
176. Hoshijima M. Gene therapy targeted at calcium handling as an approach to
177. Zhang R, Khoo MS, Wu Y et al. Calmodulin kinase II inhibition protects against structural heart disease. Nat. Med. 11(4), 409-417 (2005).
178. Kaye DM, Krum H. Drug discovery for heart failure: a new era or the end of the pipeline? Nat. Rev. Drug Discov. 6(2), 127-139 (2007).
179. Hajjar RJ, Zsebo K, Deckelbaum L et al. Design of a Phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J. Card. Fail. 14(5), 355-367 (2008).
180. Dimmeler S, Zeiher AM, Schneider MD. Unchain my heart: the scientific foundations of cardiac repair. J. Clin. Invest. 115(3), 572-583 (2005).
181. Anversa P, Kajstura J, Leri A. If I can stop one heart from breaking. Circulation 115(7), 829-832 (2007).
182. Daley GQ, Scadden DT. Prospects for stem cell-based therapy. Cell 132(4), 544-548 (2008).
183. Segers VF, Lee RT. Stem-cell therapy for cardiac disease. Nature 451(7181), 937-942 (2008).
184. Gersh BJ, Simari RD, Behfar A, Terzic CM, Terzic A. Cardiac cell repair therapy: a clinical perspective. Mayo Clin. Proc. 84(10), 876-892 (2009).
185. Rubart M, Field LJ. Cardiac repair by embryonic stem-derived cells. Handb. Exp. Pharmacol. (174), 73-100 (2006).
186. Nadal-Ginard B, Kajstura J, Leri A, Anversa P. Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. Circ. Res. 92(2), 139-150 (2003).
187. Soldner F, Hockemeyer D, Beard C et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136(5), 964-977 (2009).
188. Zhang J, Wilson GF, Soerens AG et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ. Res. 104(4), e30-e41 (2009).
189. Nelson TJ, Martinez-Fernandez A, Yamada S, Perez-Terzic C, Ikeda Y, Terzic A. Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation 120(5), 408-416 (2009).
190. Soonpaa MH, Field LJ. Survey of studies examining mammalian cardiomyocyte DNA synthesis. Circ. Res. 83(1), 15-26 (1998).
191. Katz EB, Steinhelper ME, Delcarpio JB, Daud AI, Claycomb WC, Field LJ. Cardiomyocyte proliferation in mice expressing a-cardiac myosin heavy chain-SV40 T-antigen transgenes. Am. J. Physiol. 262(6 Pt 2), H1867-H1876 (1992).
192. Chaudhry HW, Dashoush NH, Tang H et al. Cyclin A2 mediates cardiomyocyte mitosis in the postmitotic myocardium. J. Biol. Chem. 279(34), 35858-35866 (2004).
193. Pasumarthi KB, Nakajima H, Nakajima HO, Soonpaa MH, Field LJ. Targeted expression of cyclin D2 results in cardiomyocyte DNA synthesis and infarct regression in transgenic mice. Circ. Res. 96(1), 110-118 (2005).
194. Nakajima H, Nakajima HO, Tsai SC, Field LJ. Expression of mutant p193 and p53 permits cardiomyocyte cell cycle reentry after myocardial infarction in transgenic mice. Circ. Res. 94(12), 1606-1614 (2004).
195. Woo YJ, Panlilio CM, Cheng RK et al. Therapeutic delivery of cyclin A2 induces myocardial regeneration and enhances cardiac function in ischemic heart failure. Circulation 114(1 Suppl.), I206-I213 (2006).
196. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ. Res. 103(11), 1204-1219 (2008).
197. Engel FB, Schebesta M, Duong MT et al. p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. Genes Dev. 19(10), 1175-1187 (2005).
198. Engel FB, Hsieh PC, Lee RT, Keating MT. FGF1/p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial infarction. Proc. Natl Acad. Sci. USA 103(42), 15546-15551 (2006).
199. Kuhn B, del Monte F, Hajjar RJ et al. Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Nat. Med. 13(8), 962-969 (2007).
200. Bersell K, Arab S, Haring B, Kuhn B. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 138(2), 257-270 (2009).
201. Spin JM, Prakash M, Froelicher VF et al. The prognostic value of exercise testing in elderly men. Am. J. Med. 112(6), 453-459 (2002).
202. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N. Engl. J. Med. 346(11), 793-801 (2002).
203. Hughes VA, Fiatarone MA, Fielding RA et al. Exercise increases muscle GLUT-4 levels and insulin action in subjects with impaired glucose tolerance. Am. J. Physiol. 264(6 Pt 1), E855-E862 (1993).
204. Toledo FG, Menshikova EV, Ritov VB et al. Effects of physical activity and weight loss on skeletal muscle mitochondria and relationship with glucose control in Type 2 diabetes. Diabetes 56(8), 2142-2147 (2007).
205. Constable SH, Favier RJ, McLane JA, Fell RD, Chen M, Holloszy JO. Energy metabolism in contracting rat skeletal muscle: adaptation to exercise training. Am. J. Physiol. 253(2 Pt 1), C316-C322 (1987).